The subscription price for the use of warrants of series TO3 in Toleranzia AB has been set at SEK 1.14 and the subscription period will start on 1 September 2021
30 August - 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Toleranzia AB (publ) ("Toleranzia" or the "Company") completed a rights issue of shares and warrants of series TO3 during the third quarter of 2020. Each warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price equal to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Growth Market during the measurement period from 16 August 2021 to 27 August 2021. During the measurement period, the volume weighted average price of the Company's share was approximately SEK 1.63 and thus the subscription price has been set at SEK 1.14. The subscription period for warrants of series TO3 starts on 1 September 2021 and runs until 15 September 2021.
If all warrants of series TO3 are exercised, the Company will receive approximately SEK 28.8 million before issue costs. In order for the warrants not to lapse without value, the holder must actively subscribe for shares no later than 15 September 2021, or alternatively sell warrants no later than 13 September 2021. Please note that some trustees may close their registration earlier than 15 September 2021.
Summary terms and conditions of the TO3 warrants:
Subscription period: 1 September – 15 September 2021.
Issue volume: 25,243,025 warrants of series TO3 entitle to subscribe for 25,243,025 shares. If fully exercised, the Company will receive approximately SEK 28.8 million before issue costs.
Subscription price: SEK 1.14 per share.
Last day for trading in warrants of series TO3: 13 September 2021.
Dilution etc.: If fully utilised, the share capital will increase by SEK 3,155,378.125, from currently SEK 6,793,255.125, to SEK 9,948,633.250. The number of shares will increase by 25 243 025 shares, from 54 346 041 shares today, to 79 589 066 shares when fully utilised. The dilution at full utilisation amounts to approximately 32 per cent of the number of shares and approximately 32 per cent of the number of votes.
Please note that the warrants that are not exercised by 15 September 2021, or alternatively disposed of by 13 September 2021, will expire worthless. Active subscription of shares or disposal of warrants is required for the warrants not to lapse.
How the warrants are used:
Trustee-registered warrants (depository)
Subscription and payment by exercise of the warrant shall be made in accordance with the instructions of the respective trustee. Please contact your trustee for further information.
Directly registered warrants (VP account)
No issue statement or payment instructions will be sent out. Subscription must be made by simultaneous cash payment as instructed on the application form. The warrants will then be replaced by interim shares pending registration with the Swedish Companies Registration Office.
Application form with instructions for payment will be available on Mangold Fondkommission AB's website www.mangold.se.
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to Toleranzia regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Telephone: +46 8 5050 1595
For further information, please contact:
Charlotte Fribert – CEO, Toleranzia
Telephone: +46 763 19 98 98
About Toleranzia AB
Toleranzia AB (556877-2866) is a Swedish biotechnology company listed on Nasdaq First North Growth Market. The company develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.